Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics
Pediatric Dermatology · 2025
DOI: 10.1111/pde.15994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Nessa Aghazadeh Mohandesi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Arthritis, Nod2 Signaling Adaptor Protein, Synovitis, Uveitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Blau syndrome is a rare, autosomal dominant granulomatous disease caused by mutations in the NOD2/CARD15 gene. While the classic triad of arthritis, dermatitis, and uveitis is well known, the full range of cutaneous manifestations remains underexplored.
Objective
To expand the understanding of cutaneous findings in Blau syndrome, correlate these findings with NOD2 variants, and evaluate treatment outcomes across organ systems.
Methods
A retrospective review of medical records from January 1999 to January 2024 identified 14 patients with Blau syndrome supported by the presence of NOD2 variants. Clinical data on dermatological features, genetics, and treatment responses were analyzed and categorized into specific and non‐specific cutaneous findings.
Results
Of the 14 patients with Blau syndrome, 85% (12/14) demonstrated skin involvement. Specific findings included lichenoid or granulomatous papules and nodules (50%, 6/12), while non‐specific findings (83%, 10/12) were more diverse, including dermatitis (6/10), chronic urticaria (5/10), ichthyosiform eruptions (4/10), vasospastic disorders (5/10), and oral/genital ulcers (2/10). Skin biopsies in three patients with specific findings revealed non‐caseating granulomas. Genetic analysis identified multiple NOD2 variants, though no clear genotype–phenotype correlation was observed. TNF‐alpha inhibitors demonstrated efficacy in controlling ocular and joint disease.
Conclusion
Blau syndrome presents with a broader spectrum of cutaneous findings than previously recognized. These findings highlight the importance of dermatological evaluation and a multidisciplinary approach to optimize diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pediatric and Adolescent Medicine, Mayo Clinic Children's, Rochester, Minnesota, USA.
- Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Setu Mittal, Amir B Orandi, Dawn Marie Davis
Zitieren
APA
Mohandesi, N. A., Mittal, S., Orandi, A. B., Smith, W. M., Khan, N. S., & Davis, D. M. (2025). Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics. Pediatric Dermatology. https://doi.org/10.1111/pde.15994
Vancouver
Mohandesi NA, Mittal S, Orandi AB, Smith WM, Khan NS, Davis DM. Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics. Pediatric Dermatology. 2025. doi:10.1111/pde.15994
BibTeX
@article{Mohandesi2025,
author = {Mohandesi, Nessa Aghazadeh and Mittal, Setu and Orandi, Amir B and Smith, Wendy M and Khan, Nila S and Davis, Dawn Marie},
title = {Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics},
journal = {Pediatric Dermatology},
year = {2025},
doi = {10.1111/pde.15994}
}
EUVIMED